Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

@article{Ong2015RelationshipOF,
  title={Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study},
  author={Kwok Leung Ong and Andrzej S Januszewski and Rachel L. O’Connell and Luke Buizen and Alicia Josephine Jenkins and Aimin Xu and David R. Sullivan and Philip J. Barter and Russell S. Scott and Marja-Riitta Taskinen and Kerry-Anne Rye and Anthony C Keech},
  journal={Diabetologia},
  year={2015},
  volume={58},
  pages={2035-2044}
}
Baseline circulating fibroblast growth factor 21 (FGF21) levels can predict total cardiovascular disease events in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. This paper describes the relationship of baseline FGF21 levels and new on-study microvascular disease in patients with type 2 diabetes from the FIELD study. Baseline FGF21 levels were measured in plasma by enzyme-linked immunosorbent assay in 9697 study participants. Total microvascular disease was defined… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 32 references

FGF-21 as a novel metabolic regulator.

The Journal of clinical investigation • 2005
View 4 Excerpts
Highly Influenced

Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease

N Ahluwalia, J Blacher, F Szabo de Edelenyi
Atherosclerosis • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…